Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1990 May;85(5):1560–1565. doi: 10.1172/JCI114605

Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.

A P Gillio 1, C Gasparetto 1, J Laver 1, M Abboud 1, M A Bonilla 1, M B Garnick 1, R J O'Reilly 1
PMCID: PMC296606  PMID: 2332507

Abstract

Interleukin-3 (IL-3) is a hematopoietic growth factor that supports the growth of early hematopoietic progenitors in vitro. In vivo administration of recombinant human interleukin-3 (rhIL-3) to normal primates results in a modest and delayed leukocytosis secondary to increases in neutrophils, basophils, and eosinophils. We postulated that the effects of rhIL-3 might be more pronounced in hematologically stressed primates, and therefore administered rhIL-3 to primates after intensive myelosuppressive therapy. Primates received either cyclophosphamide (CPM) at 60 mg/kg or 5-fluorouracil (5-FU) at 75 mg/kg i.v. on two consecutive days. Subsequently, rhIL-3 was administered intravenously or subcutaneously at 20 micrograms/kg per d for 14 d. Compared to controls, all rhIL-3 treated primates experienced higher absolute neutrophil count (ANC) nadirs and dramatic decreases in the period of severe neutropenia (ANC less than 500) after myelosuppressive therapy. RhIL-3 administration resulted in a significant basophilia and eosinophilia, which resolved after discontinuation of the drug. RhIL-3 did not enhance erythroid recovery. Platelet recovery was earlier in rhIL-3-treated animals. However, variations in the platelet recovery observed in control animals, precluded accurate estimation of this effect or its significance. Our results indicate that the administration of rhIL-3 following intensive myelosuppressive therapy dramatically enhances myeloid recovery and ablates the predicted period of prolonged severe neutropenia.

Full text

PDF
1560

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bot F. J., van Eijk L., Schipper P., Löwenberg B. Effects of human interleukin-3 on granulocytic colony-forming cells in human bone marrow. Blood. 1989 Apr;73(5):1157–1160. [PubMed] [Google Scholar]
  2. Briddell R. A., Brandt J. E., Straneva J. E., Srour E. F., Hoffman R. Characterization of the human burst-forming unit-megakaryocyte. Blood. 1989 Jul;74(1):145–151. [PubMed] [Google Scholar]
  3. Bruno E., Miller M. E., Hoffman R. Interacting cytokines regulate in vitro human megakaryocytopoiesis. Blood. 1989 Feb 15;73(3):671–677. [PubMed] [Google Scholar]
  4. Donahue R. E., Seehra J., Metzger M., Lefebvre D., Rock B., Carbone S., Nathan D. G., Garnick M., Sehgal P. K., Laston D. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science. 1988 Sep 30;241(4874):1820–1823. doi: 10.1126/science.3051378. [DOI] [PubMed] [Google Scholar]
  5. Donahue R. E., Wang E. A., Stone D. K., Kamen R., Wong G. G., Sehgal P. K., Nathan D. G., Clark S. C. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. 1986 Jun 26-Jul 2Nature. 321(6073):872–875. doi: 10.1038/321872a0. [DOI] [PubMed] [Google Scholar]
  6. Haak-Frendscho M., Arai N., Arai K., Baeza M. L., Finn A., Kaplan A. P. Human recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3 cause basophil histamine release. J Clin Invest. 1988 Jul;82(1):17–20. doi: 10.1172/JCI113567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hodgson G. S., Bradley T. R., Radley J. M. The organization of hemopoietic tissue as inferred from the effects of 5-fluorouracil. Exp Hematol. 1982 Jan;10(1):26–35. [PubMed] [Google Scholar]
  8. Mayer P., Valent P., Schmidt G., Liehl E., Bettelheim P. The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood. 1989 Aug 1;74(2):613–621. [PubMed] [Google Scholar]
  9. Niemeyer C. M., Sieff C. A., Mathey-Prevot B., Wimperis J. Z., Bierer B. E., Clark S. C., Nathan D. G. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood. 1989 Mar;73(4):945–951. [PubMed] [Google Scholar]
  10. Ottmann O. G., Abboud M., Welte K., Souza L. M., Pelus L. M. Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors. Exp Hematol. 1989 Feb;17(2):191–197. [PubMed] [Google Scholar]
  11. Saito H., Hatake K., Dvorak A. M., Leiferman K. M., Donnenberg A. D., Arai N., Ishizaka K., Ishizaka T. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2288–2292. doi: 10.1073/pnas.85.7.2288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sieff C. A., Ekern S. C., Nathan D. G., Anderson J. W. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood. 1989 Feb 15;73(3):688–693. [PubMed] [Google Scholar]
  13. Sonoda Y., Yang Y. C., Wong G. G., Clark S. C., Ogawa M. Analysis in serum-free culture of the targets of recombinant human hemopoietic growth factors: interleukin 3 and granulocyte/macrophage-colony-stimulating factor are specific for early developmental stages. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4360–4364. doi: 10.1073/pnas.85.12.4360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sonoda Y., Yang Y. C., Wong G. G., Clark S. C., Ogawa M. Erythroid burst-promoting activity of purified recombinant human GM-CSF and interleukin-3: studies with anti-GM-CSF and anti-IL-3 sera and studies in serum-free cultures. Blood. 1988 Oct;72(4):1381–1386. [PubMed] [Google Scholar]
  15. Valent P., Schmidt G., Besemer J., Mayer P., Zenke G., Liehl E., Hinterberger W., Lechner K., Maurer D., Bettelheim P. Interleukin-3 is a differentiation factor for human basophils. Blood. 1989 May 15;73(7):1763–1769. [PubMed] [Google Scholar]
  16. Van Zant G. Studies of hematopoietic stem cells spared by 5-fluorouracil. J Exp Med. 1984 Mar 1;159(3):679–690. doi: 10.1084/jem.159.3.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Welte K., Bonilla M. A., Gillio A. P., Boone T. C., Potter G. K., Gabrilove J. L., Moore M. A., O'Reilly R. J., Souza L. M. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987 Apr 1;165(4):941–948. doi: 10.1084/jem.165.4.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yang Y. C., Ciarletta A. B., Temple P. A., Chung M. P., Kovacic S., Witek-Giannotti J. S., Leary A. C., Kriz R., Donahue R. E., Wong G. G. Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell. 1986 Oct 10;47(1):3–10. doi: 10.1016/0092-8674(86)90360-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES